Disease management programs for patients with type 2 diabetes mellitus in Germany: a longitudinal population-based descriptive study

Diabetology & Metabolic Syndrome
Michael MehringAntonius Schneider

Abstract

The primary aim of the disease management program (DMP) for patients with diabetes mellitus type 2 is to improve the quality of health care and the treatment process. 12 years after its introduction in Germany, there is still no consensus as to whether DMP has been effective in reaching these goals. A retrospective longitudinal population-based study between 2004 and 2015 were conducted to evaluate the DMP for type 2 diabetes in Bavaria using routinely collected patient medical records hold from the National Association of Statutory Health Insurance Physicians of Bavaria. During the first 12 years of DMP, the number of participants increased continually to reach 580,222 in 2015. The proportion of participants older than 70 years increased during the observation from 41.6 to 51.1%. The percentage of smokers increased slightly from 9 to 11%. Similarly, the distribution of body mass index remained constant with approximately 50% of patients having a body mass index >30 kg/m(2). Control of HbA1c was without an appreciable change over the course, with between 8.3 and 9.4% of all patients with uncontrolled values higher than 8.5%. Prescription of metformin increased from 40.5% in 2004 to 54.1% in 2015. Among patients receiving insuli...Continue Reading

References

May 3, 2002·American Journal of Preventive Medicine·Susan L NorrisDavid McCulloch
Jan 19, 2006·Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·M Morfeld, M Wirtz
Feb 11, 2011·Diabetes/metabolism Research and Reviews·Reneé G StarkUNKNOWN KORA Study Group
Jun 2, 2016·Journal of Diabetes Science and Technology·Karel KostevLouis Jacob

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy

Software Mentioned

R environment

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.